Therapeutic effect of berberine on chronic atrophic gastritis based on plasma and urine metabolisms.
Berberine
Chronic atrophic gastritis
Metabolomics
Molecular mechanisms
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Oct 2021
05 Oct 2021
Historique:
received:
27
03
2021
revised:
19
06
2021
accepted:
11
07
2021
pubmed:
16
7
2021
medline:
7
1
2022
entrez:
15
7
2021
Statut:
ppublish
Résumé
The purpose of this study was to investigate the therapeutic effect of berberine (BBR) on chronic atrophic gastritis (CAG) and its potential mechanism. The effects of BBR on gastric histopathology, serum biochemical indexes and inflammatory factors in CAG rats were assessed. Moreover, plasma and urine metabolomics based on ultra high performance liquid chromatography-quadrupole-time-of-flight mass spectrometer (UHPLC-Q-TOF/MS) were used to identify potential metabolic markers and possible pathways of BBR in the treatment of CAG. The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-κB, tumor necrosis factor-α, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-γ. The results of metabolomic analysis show that the therapeutic effect of BBR on CAG may be related to the regulation of 15 metabolic markers and 12 metabolic pathways, which may be the potential mechanism for the treatment of CAG. This study provides new insights for elucidating the mechanism of BBR improving CAG.
Identifiants
pubmed: 34265298
pii: S0014-2999(21)00488-X
doi: 10.1016/j.ejphar.2021.174335
pii:
doi:
Substances chimiques
Interleukin-17
0
Berberine
0I8Y3P32UF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174335Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.